• William N Whiteley, Douglas Thompson, Gordon Murray, Geoff Cohen, Richard I Lindley, Joanna Wardlaw, Peter Sandercock, and IST-3 Collaborative Group.
• From the Centre for Clinical Brain Sciences (W.N.W., G.C., J.W., P.S.) and Centre for Population Health Sciences (D.T., G.M.), University of Edinburgh, United Kingdom; Neurological & Mental Health Division, George Institute for Global Health, University of Sydney, Australia (R.I.L.); and Neuroimaging Sciences, Edinburgh, United Kingdom (J.W.). william.whiteley@ed.ac.uk.
• Stroke. 2014 Dec 1;45(12):3612-7.

Background And PurposePrompt thrombolytic therapy with intravenous alteplase reduces disability after acute ischemic stroke. In an exploratory analysis, we examined whether long-term survival varied by baseline characteristics after alteplase.MethodsIn this open-treatment, international, randomized, controlled trial, ischemic stroke patients were randomly allocated <6 hours of onset to intravenous alteplase (0.9 mg/kg) plus standard care (n=1515) or standard care alone (n=1520). We followed patients to death, censoring when last known to be alive. We grouped patients by delay to randomization, and good or poor predicted prognosis (calculated from baseline National Institutes of Health Stroke Scale [NIHSS] score and age). We present absolute mortality differences between treated and control groups at 7 days, 6 months, and 18 months poststroke.ResultsAlteplase was not associated with a significant increase in mortality within 18 months (0.6% [95% confidence interval (CI), -2.9% to +4.2] P=0.72] in all patients with complete vital status (99.9%, 3034/3035). In patients randomized <3 hours of stroke, 18-month mortality was lower in the alteplase-treated group than the control group (40.6% [95% CI, 42.6-52.7] versus 47.8% [95% CI, 35.5-45.3]; P=0.0434]. The difference in 18-month mortality between alteplase-treated and control patients was greater in patients who were randomized early (<3 hours) compared with late (3-6 hours; +9% [95% CI, 1-17]; P=0.0317). Alteplase led to a greater improvement in 18-month survival in patients with a poor prognosis than in patients with a good prognosis (+8% [95% CI, 2-14]; P=0.0091).ConclusionsThese exploratory analyses of the third International Stroke Trial (IST-3) trial support improving acute stroke patients' access to earlier alteplase treatment, treatment of patients with poor prognosis, and further randomized controlled trials in minor stroke to replicate these findings.Clinical Trial Registration Urlhttp://www.controlled-trials.com. Unique identifier: ISRCTN25765518.© 2014 American Heart Association, Inc.

18 keywords...

hide…